While imatinib is considered standard-of-care, there is a lack of clinical data for the treatment among elderly patients. Researchers found that patients with diabetes and higher alpha-fetoprotein had decreased OS rates. TNT with induction chemoimmunotherapy and long-course chemoradiation may lead to high CR in high-risk, pMMR rectal cancer. Surgical treatment combined with targeted therapy may improve OS and CSS in patients with GIST-SLM. A final overall survival and updated safety analysis from the phase 3 INTRIGUE study. For patients with NETs, somatostatin receptors are often targeted for nuclear theranostics applications. Results of the PANDA study show that atezo has an additive effect with chemo in eliciting tumor response in early G/GEJ. Patients randomly received either TACE plus durvalumab and bevacizumab, TACE plus durvalumab, or TACE alone. Both CD8IE and FoxP3IS showed independent prognostic value as RFS markers in bivariable and multivariable analyses. The NAPOLI 3 study demonstrated improved OS and PFS in patients with metastatic pancreatic cancer and no prior chemotherapy. Future trials for resectable pancreatic ductal adenocarcinoma should be driven by patient biomarkers. Nivolumab plus ipilimumab showed significant improvement in progression-free survival in patients in the first line setting. The developed nomogram was found to provide significant diagnostic accuracy with an area under the curve level of 0.882. The study investigated if avelumab and paclitaxel plus ramucirumab would constitute an effective second-line treatment. Investigators compared the benefits of a nomogram with the AJCC staging system in predicting overall survival. The ELI-002 vaccine uses T cells to identify and remove tumor cells containing KRAS G12D- or G12R-mutated cancer. In patients with HCC, a high CD8 and low TIM3 expression is linked to better OS than PD-1/PD-L1. Meta-analysis data has shown that HAIP combined with systemic chemotherapy can provide a pooled 3-year OS rate of 39.5%. GLP-1RAs are linked to a decreased risk of CRC compared with insulin and other antidiabetic drugs. Dr. Abdilleh discusses PanCAN's new cloud-based data and analytics program for pancreatic cancer research.